What Mounjaro Contains — and Why It Works Differently

Where tirzepatide comes from, and what it mimics

Tirzepatide is a lab-synthesised molecule designed to resemble two naturally occurring gut hormones: GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). Both hormones are released by the gut after eating and play a role in appetite signalling, insulin secretion and how quickly food moves through the stomach. The SURMOUNT-1 trial, published in the New England Journal of Medicine, studied tirzepatide in over 2,500 adults with obesity over 72 weeks and reported an average body-weight reduction of around 20–21% at the 15 mg dose, figures that put tirzepatide among the most effective medicines in this class. The dual-receptor design is why Mounjaro sits in a different category from medicines that act on GLP-1 alone. You can read more about how tirzepatide relates to the GLP-1 pathway specifically, because the distinction matters for understanding both its effects and its side-effect profile.

Eli Lilly, Mounjaro's manufacturer, developed tirzepatide as a single molecule that binds to both receptors, not a mixture of two separate drugs. If you've ever been curious about what the name Mounjaro actually means, it turns out the story behind it adds some useful context to how the treatment was positioned from the start. The GIP component appears to enhance the appetite-suppressing effect beyond what GLP-1 receptor activation alone achieves, though exactly how the two pathways interact is still an active area of research.

What else is in the pen, the inactive ingredients

Alongside tirzepatide, the Mounjaro KwikPen solution contains a small set of excipients: sodium phosphate dibasic heptahydrate and sodium phosphate monobasic monohydrate (buffering agents that keep the pH stable), mannitol (a sugar alcohol used as a tonicity agent), polysorbate 80 (a surfactant that prevents aggregation of the tirzepatide molecule) and water for injections. None of these has any pharmacological action at the concentrations present in the pen. If you have a known allergy to any of these components, that's something to raise directly with a prescriber before starting treatment, it's exactly the kind of detail a clinical assessment is designed to surface. The full list, with quantities, is in the Mounjaro SmPC held on the Electronic Medicines Compendium (eMC).

One thing Mounjaro does not contain is insulin. This is a common question, perhaps because Mounjaro is also licensed to treat type 2 diabetes, and people assume a diabetes medicine must involve insulin. It doesn't. A closer look at whether Mounjaro contains insulin explains the distinction if you want the full detail, but the short answer is no.

The six strengths and what changes between them

Mounjaro is available in six doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, all containing tirzepatide as the same active substance. The excipients are identical across strengths; what changes is simply the concentration of tirzepatide in the solution. Treatment begins at 2.5 mg, a starting level chosen to let the body adjust rather than to produce the full therapeutic effect. A prescriber then steps the dose up in roughly four-week intervals, based on how the treatment is being tolerated. If you're wondering which medications and products contain tirzepatide, our dedicated page covers the full picture alongside the dose schedule and what to expect at each stage.

From a practical standpoint, the KwikPen format means there is no drawing up, no mixing and no separate needle to attach before injecting. Each pen is pre-filled and pre-set to the correct dose. Used pens need safe disposal, if you don't have a sharps container, our page on sharps disposal for Mounjaro covers the options. Storage follows refrigeration between 2°C and 8°C; the exact room-temperature window after removal from the fridge is stated in the Patient Information Leaflet, and the prescriber or the PIL should always be the reference point for that detail.

What this means for eligibility and clinical assessment

Understanding what Mounjaro contains is useful background, but the ingredient list doesn't determine whether it's right for you, that's a clinical judgement. The UK licence covers adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK guidance. A prescriber also considers existing medications, medical history, and any contraindications before a prescription is issued. Mounjaro is a prescription-only medicine; no online service can legally supply it without that assessment taking place. For a broader look at how Mounjaro works as a treatment, or to understand the range of weight-loss treatment options available, those pages set out the full picture. When you're ready, checking your eligibility through a free consultation is the practical next step.